CLAIM AMENDMENTS

1. Use of a composition comprising a vector carrying Nurr1 and Foxa2 genes in the manufacture of a medicament for the treatment of tauopathy caused by tau protein phosphorylation.

2. The use of claim 1, wherein the vector is a viral vector or a non-viral vector.

3. Use of a composition comprising neurons or glia having Nurr1 and Foxa2 genes introduced thereinto in the manufacture of a medicament for the treatment of tauopathy caused by tau protein phosphorylation.

4. The use of claim 3, wherein the glia are astrocytes or microglia.

5 Use of a composition comprising a vector carrying Nurr1 and Foxa2 genes in the manufacture of a medicament for the treatment of tauopathy caused by tau protein accumulation, aggregation, or tangle.

6. The use of claim 5, wherein the vector is a viral vector or a non-viral vector.

7 Use of a composition comprising neurons or glia having Nurr1 and Foxa2 genes introduced thereinto in the manufacture of a medicament for the prevention or treatment of tauopathy caused by tau protein accumulation, aggregation, or tangle.

8. The use of claim 7, wherein the glia are astrocytes or microglia.

9. The use of any one of claims 1-8, wherein the tauopathy is a disease selected from the group consisting of tau-positive Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia (FTD), multi-Infarct dementia (MID), frontotemporal lobar degeneration (FTLD), progressive cupranuclear palsy (PSP), Pick’s disease, chronic traumatic encephalopathy (CTE), corticobasal degeneration (CBD), globular glial tauopathy, Huntington's disease, ganglioglioma, gangliocytoma, primary age-related tauopathy (PART), argyrophilic grain disease, lead encephalopathy, lipofuscinosis, Lytico-Bodig disease, and meningioangiomatosis.